Deciphering elevated risk of life-threatening hemorrhage and early death in acute myeloid leukemia with APL-like phenotype: independent role of endothelial injury and implications of EASIX-based risk stratification in a multicenter study.
A blood test pinpoints which leukemia patients face life-threatening bleeding, allowing doctors to adjust treatment doses upfront and improve survival in this vulnerable group.
In a large multicenter Chinese cohort (n=344 APLL), EASIX (endothelial activation and stress index) quantifies endothelial injury that independently drives hemorrhage risk in AML with APL-like phenotype, identifying a high-risk subgroup with significantly elevated early death. A modified venetoclax + HMA regimen with reduced VEN initiation dose improved early outcomes in high-risk APLL, offering an immediately actionable risk-stratified approach.
What the study was
- Study design
- Multicenter retrospective cohort with propensity score matching and prospective biomarker validation
- Population
- AML patients (n=344 APLL, n=212 APL, n=1596 other AML) from three Chinese institutions
- Sample size
- 2152
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Journal of Translational Medicine
Why it surfaced
Large multicenter Chinese cohort with real-world translational finding: EASIX risk stratification directly enables clinical decision-making for AML patients with APL-like phenotype, and the modified VEN-HMA regimen result is practice-relevant.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.